The immunobiology of photodynamic therapy: the potential for therapeutic intervention in lung cancer.
Studies have shown that photodynamic therapy (PDT) causes or enhances an antitumor immune response. Moving from a mouse model in lung cancer to a translational approach, researchers are conducting an ongoing observational study to determine whether the immune response in patients with lung cancer treated with PDT is mediated by a T-cell phenotype, which may result in decreased tumor size and potentially improve survival. Preliminary findings focus on certain inflammatory cytokines that may be predictive of these T-cell phenotypes, such as interleukin (IL)-12, IL-4, T-regulatory cells, and T helper 17 cells. Correlation of the immunobiology of PDT associated with outcomes and surrogate markers may allow clinicians to predict improvement in patients treated with PDT and improve prognostic counseling.
College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA. susan.moffatt-bruce@osumc.edu
Susan
S
Moffatt-Bruce
D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D006801:Humans; D018664:Interleukin-12 / Q000032:analysis; D015847:Interleukin-4 / Q000032:analysis; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D051379:Mice; D010778:Photochemotherapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D058504:Th17 Cells / Q000276:immunology; D016896:Treatment Outcome
D018664:Interleukin-12; D015847:Interleukin-4